Vivos Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 16% in 2025, driven by SCN acquisition and a shift to a medical provider model, offsetting legacy declines. Gross margin held at 60%, but net loss widened due to integration costs. Expansion, insurance access, and SO team deployment are expected to drive growth in 2026.
-
A transformative year saw a strategic pivot to a vertically integrated model, driving a 76% revenue surge and high EBITDA margins. Rapid expansion, improved insurance coverage, and new affiliate partnerships position the company for national growth and industry consolidation.
-
Q3 2025 saw revenue jump 76% year-over-year, driven by the SCN acquisition and new treatment centers, while net loss widened due to upfront costs. Management expects continued strong growth, improved margins, and cash flow break-even as new providers are onboarded and affiliations expand.
-
Q2 2025 saw a strategic pivot with the SCN acquisition, driving sequential revenue growth and strong demand for new SO teams, despite a year-over-year revenue decline and higher operating losses from integration costs. Management expects cash flow positivity by Q4 2025 as expansion continues.
-
Q1 2025 saw a strategic pivot to acquiring sleep medical providers, with product sales up 8% but total revenue down due to lower service revenue. The SCN acquisition is expected to be immediately accretive, with positive cash flow forecast by year-end 2025.
-
The discussion highlighted a strategic pivot from dental to direct medical engagement, leveraging recent FDA clearances to treat all levels of sleep apnea. The company expects significant growth and improved margins through new alliances and vertical integration, with financial impact anticipated in 2025.
Fiscal Year 2024
-
Revenue grew 9% to $15M in 2024, driven by a 26% increase in product sales and a strategic shift to alliances and acquisitions. Operating loss fell 35% as costs were cut, and new FDA clearances and international expansion set the stage for stronger growth in 2025.
-
Q3 2024 saw 17% revenue growth and improved gross margins, with cost reductions driving a 27% decrease in operating loss. The company is transitioning to a new alliance-based model, expecting significant revenue growth and a path to positive cash flow by mid-2025.
-
Q2 2024 saw 19% revenue growth and a 65% reduction in net loss, driven by higher product sales, reduced discounts, and cost controls. Strategic alliances and a $7.5M equity investment position the company for accelerated growth and positive cash flow.